Reactogenicity, immunogenicity and breakthrough infections following heterologous or fractional second dose COVID-19 vaccination in adolescents (Com-COV3): A randomised controlled trial.
Kelly E, Greenland M, de Whalley PCS, Aley PK, Plested EL, Singh N, Koleva S, Tonner S, Macaulay GC, Read RC, Ramsay M, Cameron JC, Turner DPJ, Heath PT, Bernatoniene J, Connor P, Cathie K, Faust SN, Banerjee I, Cantrell L, Mujadidi YF, Belhadef HT, Clutterbuck EA, Anslow R, Valliji Z, James T, Hallis B, Otter AD, Lambe T, Nguyen-Van-Tam JS, Minassian AM, Liu X, Snape MD; Com-COV3 Study Group.
Kelly E, et al. Among authors: de whalley pcs.
J Infect. 2023 Sep;87(3):230-241. doi: 10.1016/j.jinf.2023.06.007. Epub 2023 Jun 17.
J Infect. 2023.
PMID: 37331429
Free PMC article.
Clinical Trial.